Cannabis Remains Federally Illegal Despite 38-State Medical Patchwork

Federal Schedule I Status Unchanged Since 1970

Cannabis has been classified as a Schedule I controlled substance under the Controlled Substances Act since 1970, a designation that defines it as having no accepted medical use and high abuse potential. The Drug Enforcement Administration maintains this classification despite decades of state-level reforms. Schedule I placement blocks FDA approval pathways, prevents interstate commerce, and triggers the Internal Revenue Code's Section 280E tax treatment that disallows ordinary business deductions for cannabis operators.

The classification stands in direct conflict with state programs. As of May 2026, 38 states permit medical cannabis and 24 allow adult-use sales. Yet every transaction in those markets technically violates the federal Controlled Substances Act. Participants face potential prosecution under 21 U.S.C. § 841.

Banking and Tax Consequences Drive Operational Risk

Federal illegality bars most banks from serving cannabis businesses, forcing operators into cash-intensive models that increase robbery risk and complicate payroll and tax compliance. The Financial Crimes Enforcement Network issued guidance in 2014 allowing banks to file Suspicious Activity Reports for cannabis clients, but fewer than 800 of the nation's 4,800 federally insured institutions accept cannabis deposits. Cash dependency costs operators an estimated 10-15% in additional overhead for armored transport, security, and manual accounting.

Section 280E of the Internal Revenue Code prohibits cannabis businesses from deducting ordinary expenses like rent, salaries, and marketing, leaving effective tax rates above 70% for many operators.

The tax burden stems from a 1982 Tax Court ruling in Edmondson v. Commissioner, which applied 280E to a cocaine trafficker. The IRS extended that precedent to state-legal cannabis in 2015. Operators can deduct cost of goods sold but nothing else. It's a structural disadvantage against alcohol and tobacco competitors.

Enforcement Gap Widens as State Programs Expand

The Justice Department has issued four separate memos since 2009 directing federal prosecutors to deprioritize state-compliant cannabis cases, but none carry binding legal force. The 2013 Cole Memo and its successors established an informal truce, instructing U.S. Attorneys to focus on diversion to minors, cartel activity, and interstate trafficking rather than licensed operators. Then-Attorney General Jeff Sessions rescinded the Cole Memo in January 2018. Few prosecutions followed.

Operators depend on prosecutorial discretion that shifts with each administration, a policy vacuum that leaves no statutory shield for state-licensed activity from federal charges. For context on the evolving federal stance, see the CannIntel topic hub on federal cannabis legalization. The Rohrabacher-Farr amendment, renewed annually since 2014, bars the Justice Department from spending funds to interfere with state medical programs, but it doesn't apply to adult-use markets and doesn't decriminalize possession or sale.

Rescheduling Proposals Stall in Administrative Process

The DEA initiated a notice-and-comment rulemaking in May 2024 to evaluate moving cannabis to Schedule III, but the proposal remains under review at the Office of Management and Budget as of May 2026. Schedule III placement would preserve federal prohibition but end 280E tax treatment and allow limited research under less restrictive protocols. It wouldn't legalize cannabis. It wouldn't resolve the state-federal conflict.

The rescheduling process requires the Department of Health and Human Services to submit a scientific recommendation to the DEA, which then conducts its own review before issuing a Notice of Proposed Rulemaking. Public comment periods and potential administrative hearings can extend the timeline by months or years. Even if finalized, Schedule III would leave cannabis in the same legal category as ketamine and anabolic steroids: controlled, prescription-only substances unavailable for over-the-counter sale.

The next procedural milestone is OMB clearance of the proposed rule, expected no earlier than Q3 2026. Until then, the 1970 classification stands.